Prolonged B‐Cell Depletion in MuSK Myasthenia Gravis Following Rituximab Treatment

Abstract

Rituximab (RTX) therapy is used increasingly to manage myasthenia gravis patients, and case series suggest particular benefit for those patients who have antibodies to muscle specific kinase (MuSK-MG).1 We report a MuSK-MG patient with persistent and severe B cell depletion 3 years after receiving RTX. A 62 year old woman developed ptosis, bulbar symptoms, and weight loss in 2000. In 2005 she developed hypercarbic respiratory failure and was eventually diagnosed with MuSK-MG. She had 3 additional hospitalizations for exacerbations, including one for crisis, and required BiPAP at night. An initial excellent response to therapeutic plasma exchange waned over time. Intravenous immunoglobulin, azathioprine, and prednisone did not provide significant improvement. In 2010, she was treated with 6 doses of 1000mg RTX over approximately 8 weeks (578 mg/m2 per infusion) and remained on prednisone and azathioprine. Following the RTX infusions she had a tenuous course and later developed progressive respiratory insufficiency and required nocturnal BiPAP. A chest CT showed no evidence of thymoma. Blood biomarker samples were drawn 34 months after RTX treatment, at which time she required supplemental oxygen. Clinical evaluation demonstrated persistent oculobulbar and facial weakness and disability (MG-composite: 23, MG-Manual Muscle Testing: 23, MG-Quality of Life-15: 30).2–5 We measured B cells by flow cytometry after staining for CD19 and identified helper and cytotoxic T cells by CD4 and CD8 expression, respectively. Polychromatic flow cytometry demonstrated 49.5% T helper and 44.7% cytotoxic T cells. Only 0.06% of lymphocytes were CD19+ B cells; naive, memory, and plasma cell subpopulations were undetectable (Figure). Repeat B cell markers performed over 36 months after her initial RTX treatment continued to show profound B cell depletion with <1% CD19+ B cells. Creatine kinase and thyroid profile were normal. She had had no serious infections. Figure Prolonged B cell depletion 34 months after rituximab treatment. Peripheral blood mononuclear cells from a healthy control, a patient with MuSK-MG, and our patient with MuSK-MG treated with rituximab were surface stained with CD19 PcP Cy5.5 conjugate. ... Following depletion with RTX, B cell populations typically recover within 12 months.6 This MuSK-MG patient had profound, prolonged B cell depletion 3 years after receiving RTX. It has been observed that recovery of B cell populations begins with naive B cells, and memory B cell regeneration may be delayed.7 However, in patients with autoimmune disease, such prolonged B cell depletion after RTX has only been reported in 2 systemic lupus erythematosus patients, both of whom were given RTX in combination with cyclophosphamide.8 In these cases, B cells remained low 5–7 years after RTX therapy. The underlying mechanism and the effect of concomitant cyclophosphamide therapy on the risk of developing prolonged B cell depletion with RTX are uncertain. In our case, it is also unclear how the unconventional RTX dosing regimen, combined with other immunosuppressive drugs, may have affected B cell recovery. Due to poor disease control, our patient continued to receive azathioprine and varying doses of prednisone, raising the risk for serious infections.9 As the use of RTX for neurologic diseases increases, clinicians need to be aware of the possibility of prolonged B cell depletion, particularly when it is combined with other immunosuppressives.